CytoSorbents Corp CTSO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CTSO is a good fit for your portfolio.
News
-
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
-
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
-
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
-
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
Trading Information
- Previous Close Price
- $0.80
- Day Range
- $0.79–0.83
- 52-Week Range
- $0.78–4.29
- Bid/Ask
- $0.78 / $0.82
- Market Cap
- $43.54 Mil
- Volume/Avg
- 46,299 / 101,906
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.15
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 186
- Website
- https://www.cytosorbents.com
Comparables
Valuation
|
Metric
|
CTSO
|
EMBC
|
ATEC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 3.28 | — |
Price/Book Value | 1.87 | — | 22.00 |
Price/Sales | 1.15 | 0.53 | 3.10 |
Price/Cash Flow | — | 5.12 | — |
Price/Earnings
CTSO
EMBC
ATEC
Financial Strength
|
Metric
|
CTSO
|
EMBC
|
ATEC
|
|---|---|---|---|
Quick Ratio | 1.39 | 1.55 | 1.86 |
Current Ratio | 1.77 | 2.20 | 2.86 |
Interest Coverage | −184.70 | 1.59 | −10.23 |
Quick Ratio
CTSO
EMBC
ATEC
Profitability
|
Metric
|
CTSO
|
EMBC
|
ATEC
|
|---|---|---|---|
Return on Assets (Normalized) | −47.73% | 12.52% | −9.89% |
Return on Equity (Normalized) | −100.43% | — | — |
Return on Invested Capital (Normalized) | −58.79% | 30.00% | −9.94% |
Return on Assets
CTSO
EMBC
ATEC
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Fsvmnhztg | Hwkwqs | $182.7 Bil | |
SYK
| Stryker Corp | Xljppdpqm | Jtg | $124.6 Bil | |
MDT
| Medtronic PLC | Cfzcvgh | Rhxdym | $105.2 Bil | |
BSX
| Boston Scientific Corp | Qmwkktc | Bvnxbbh | $99.1 Bil | |
EW
| Edwards Lifesciences Corp | Sjvczmcl | Bqyfvj | $52.0 Bil | |
DXCM
| DexCom Inc | Cztgtmzn | Khfc | $51.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Zbftghnyw | Vxrtn | $24.5 Bil | |
ALGN
| Align Technology Inc | Lhpldkx | Wgpbkj | $22.7 Bil | |
PHG
| Koninklijke Philips NV ADR | Qcjypjdh | Gqwfc | $18.3 Bil | |
PODD
| Insulet Corp | Wzzgrzxg | Ddrcpp | $11.6 Bil |